ORPHA:2122
Kaposiform hemangioendothelioma
Publications
1,218
Trials
11
Interventional, condition-specific
Researchers
1,017
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, locally aggressive, cutaneous or visceral vascular tumor characterized by either superficial lesions presenting as blue-purple infiltrated ill-defined plaques, or deep lesions usually manifesting with coagulation abnormality. They are associated in about 3 out of 4 of cases with potentially lethal thrombocytopenia and consumption coagulopathy (Kasabach-Merritt phenomenon; KMP).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016236
- MeSH:C537007
- UMLS:C1367420
- NCIT:C27510
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,218 matched papers (831 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
11 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,218
1,218 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,218 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
831 in the last 10 years · low confidence
Phrase hits: 1,218 · MeSH hits: 0
Who's working on it?
1,017
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ji Y19 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 02Zhou J15 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 03Qiu T12 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 04Chen S10 papers · 2026
Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 05Lan Y10 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 06Zhang Z9 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 07Gong X8 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 08Zhang X8 papers · 2026
Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 09Zhang Y8 papers · 2026
Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 10Wang Z7 papers · 2026
Department of Pediatric Surgery, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
11
interventional trials for this specific condition
11 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 13 trials are registered for hemangioendothelioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
11 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 92.1th percentile).
low confidence · 92.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
11 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07131644·NOT YET RECRUITING·Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
Conditions: Kaposiform Hemangioendothelioma·Matched via name phrase
- NCT07656909·RECRUITING·Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Conditions: Kaposiform Hemangioendothelioma (KHE) · Kasabach Merritt Phenomenon·Matched via name phrase
Broader category: hemangioendothelioma
13
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07104331·RECRUITING·SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Conditions: Epithelioid Hemangioendothelioma (EHE)·Matched via name phrase
- NCT07684287·NOT YET RECRUITING·A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
Conditions: Epithelioid Hemangioendothelioma·Matched via name phrase
- NCT07477548·NOT YET RECRUITING·A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Conditions: Vascular Malformations · Arteriovenous Malformations · Venous Malformation · Lymphangioma·Matched via name phrase
- NCT06452160·RECRUITING·A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Conditions: Mesothelioma · Epithelioid Hemangioendothelioma(EHE) · Solid Tumor·Matched via name phrase
- NCT03967834·RECRUITING·Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Conditions: Soft Tissue Sarcoma · Clear Cell Sarcoma · Epithelioid Sarcoma · Perivascular Epithelioid Cell Neoplasms·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05351216·RECRUITING·The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
Conditions: Kaposiform Hemangioendothelioma·Matched via name phrase
- NCT02399527·RECRUITING·Lymphatic Anomalies Registry for the Assessment of Outcome Data
Conditions: Lymphatic Malformation · Generalized Lymphatic Anomaly (GLA) · Central Conducting Lymphatic Anomaly · CLOVES Syndrome·Matched via name phrase
- NCT03001180·RECRUITING·Identification of Biomarkers for Patients with Vascular Anomalies
Conditions: Vascular Anomaly · Generalized Lymphatic Anomaly · Kaposiform Hemangioendothelioma · Kaposiform Lymphangiomatosis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Kaposiform hemangioendothelioma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Kaposiform hemangioendothelioma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 11 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemangioendothelioma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1218) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T19:11:14.863Z
